Pulmonary Embolism in Covid-19 Pandemic: A Threat to Recovery of the Infected Patients
Emmanuel Ifeanyi Obeagu
*
Department of Medical Laboratory science, Imo State University, Owerri, Nigeria.
Quratulain Babar
Department of Biochemistry, Government College University, Faisalabad, Pakistan.
C. C. N. Vincent
Department of Nursing Science, Imo State University, Owerri, Nigeria.
Chukwuma J. Okafor
Department of Pathology and Biochemistry, State University of Zanzibar, Tanzania.
Richard Eze
Department of Medical Laboratory Science, Madonna University Nigeria, Elele Campus, Rivers State, Nigeria.
Udunma Olive Chijioke
Department of Health Administration and Management, Faculty of Health Sciences, University of Nigeria, Enugu Campus, Enugu State, Nigeria
Adaobi Maryann Ibekwe
Department of Nursing Science, Nnamdi Azikiwe University,Nnewi Campus, Nnewi, Anambra State, Nigeria.
Immaculata Ogochukwu Uduchi
Department of Medical Laboratory Science, Nnamdi Azikiwe University, Nnewi Cmpus, Nnewi, Anambra State, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 is a new type of coronavirus that can cause Coronavirus Disease 2019 (Covid-19) and is associated with an increased risk of thrombosis-related pulmonary embolism. Globally, doctors have revised their management strategies for suspected and confirmed PD in patients with Coronavirus disease (Covid-19) in 2019. Choosing the right drug and the right dose requires consideration of potential comorbidities, which can be explained by the direct and indirect pathological consequences of Covid-19, complement activation, cytokine release, endothelial dysfunction, and the interaction between different types of blood cells. Discuss the pathophysiological events, therapeutic mortality strategies, risk factors and clinical management of patients with Covid-19 pulmonary embolism.
Keywords: Pulmonary embolism, Covid 19 pandemic, haemostasis, threat to recovery